🔬 A post hoc analysis of the EMERALD-1 study presented at @ASCO #GI25 has revealed the benefits of #durvalumab + #bevacizumab + #TACE for certain patients with #HCC.

💊 Learn what investigators found when comparing the combination against placebo:
#GI25 #durvalumab #bevacizumab #TACE #HCC